TrialObesity (Silver Spring, Md.)2026

Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.

Jesús Argente et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.